Wided Najahi Missaoui, Pharm.D., M.S., Ph.D.

Pharmaceutical and Biomedical Sciences
Lecturer

Pharmaceutical and Biomedical Sciences

Education

Ph.D. Pharmaceutical and Biomedical Sciences. College of Pharmacy, The University of Georgia, Athens, GA, USA (2018)

Master of Science, Pharmaceutics. The University of Iowa, Iowa City, Iowa, USA (2012)

National Association of Boards of Pharmacists: Foreign Pharmacy Graduate Equivalency Certificate, USA (2009)

Master of Science, Biochemistry and Molecular Biology. Department of Biochemistry and Molecular Biology. The University of Georgia, Athens, Georgia, USA (2003)

PharmD (State Diploma of Pharmacy). College of Pharmacy Monsatir, Tunisia (1994 – 1999)

Areas of Expertise

Dr. Najahi-Missaoui’s areas of interest include nanoparticulate drug delivery systems such as liposomes to target therapies for cancers including prostate and breast cancers. Her overall goal is to integrate the pathophysiology of cancer with the pharmacology of these drug delivery systems to develop more efficient targeted cancer therapies.

Honors, Awards, and Achievements

First recipient of International Society of Pharmaceutical Engineering (ISPE) Women in Pharma Scholarship (2017)

Featured on ISPE website https://ispe.org/ispeak/first-women-in-pharma-scholarship-awarded

Achievement Rewards for College Scientists (ARCS) (2014)

Achievement Rewards for College Scientists (ARCS) (2015)

Achievement Rewards for College Scientists (ARCS) (2016)

The National Scholars Honor Society

Travel award to the Southern Translational Education and Research (STaR) Conference (2016)

Affiliations

National Association of Boards of Pharmacy, Foreign Pharmacy Graduate Equivalency Committee Certificate (USA).

The National Scholars Honor Society

American Association of Pharmaceutical Scientists (AAPS)

National Association of Boards of Pharmacy (Tunisia)

International Society of Pharmaceutical Engineering (ISPE)

Selected Publications

Wided Najahi-Missaoui, Nhat D. Quach, Amber Jenkins, Isha Dabke, Payaningal R. Somanath and Brian S. Cummings. 2019. Effect of p21 Activated Kinase (PAK-1) inhibition on Cancer Cell Growth, Migraiton and Invasion. Pharmacology Research and Prespectives.

Wided N. Missaoui, Robert D. Arnold, Brian S. Cummings. 2018. Toxicological Status of Nanoparticles: What We Know and What We Don’t Know. Chemico-Biological Interactions.

Ahmad Al-Azayzih*, Wided N. Missaoui*, Brian S. Cummings, and Payaningal R. Somanath. 2016. Liposomal-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo. Nanomedicine: Nanotechnology, Biology and Medicine (impact factor 6) 12(5):1231-1239.

Amy E. Medlock; Wided Najahi-Missaoui; Teresa A. Ross; Tamara A. Dailey; Joseph Burch; Jessica R. O’Brien; William N. Lanzilotta; Harry A. Dailey. 2012. Identification and characterization of solvent-filled channels in human ferrochelatase. Biochemistry  51(27):5422-5433.

Dailey Harry A; Wu Chia-Kuei; Horanyi Peter; Medlock Amy E; Najahi-Missaoui-Wided; Burden Amy E; Dailey Tamara A; Rose John. 2007. Altered orientation of active site residues in variants of human ferrochelatase. Evidence for a hydrogen bond network involved in catalysis. Biochemistry 46 (27):7973-9.

Wided Najahi-Missaoui, and Harry A. Dailey. 2005. Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases. Blood: Journal of the American Society of Hematology (impact factor 16) 106 (3): 1098-1104.

Whatley SD, Mason NG, Khan M, Zamiri M, Badminton MN, Missaoui WN, Dailey TA, Dailey HA, Douglas WS, Wainwright NJ, Elder GH. 2004. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. Journal of Medical Genetics 41 (8):e105.